- Home
- SWTX vs TCBI Comparison
SWTX vs TCBI Comparison
Compare SWTX & TCBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- TCBI
- Stock Information
- Founded
- SWTX 2017
- TCBI 1996
- Country
- SWTX United States
- TCBI United States
- Employees
- SWTX N/A
- TCBI N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- TCBI Major Banks
- Sector
- SWTX Health Care
- TCBI Finance
- Exchange
- SWTX Nasdaq
- TCBI Nasdaq
- Market Cap
- SWTX 3.5B
- TCBI 2.9B
- IPO Year
- SWTX 2019
- TCBI N/A
- Fundamental
- Price
- SWTX $46.67
- TCBI $71.47
- Analyst Decision
- SWTX Buy
- TCBI Hold
- Analyst Count
- SWTX 7
- TCBI 15
- Target Price
- SWTX $56.86
- TCBI $76.67
- AVG Volume (30 Days)
- SWTX 4.9M
- TCBI 362.9K
- Earning Date
- SWTX 05-09-2025
- TCBI 07-17-2025
- Dividend Yield
- SWTX N/A
- TCBI N/A
- EPS Growth
- SWTX N/A
- TCBI N/A
- EPS
- SWTX N/A
- TCBI 1.74
- Revenue
- SWTX $219,670,000.00
- TCBI $891,496,000.00
- Revenue This Year
- SWTX $79.29
- TCBI $44.80
- Revenue Next Year
- SWTX $70.79
- TCBI $9.26
- P/E Ratio
- SWTX N/A
- TCBI $41.09
- Revenue Growth
- SWTX 730.42
- TCBI N/A
- 52 Week Low
- SWTX $28.21
- TCBI $56.24
- 52 Week High
- SWTX $62.00
- TCBI $91.80
- Technical
- Relative Strength Index (RSI)
- SWTX 60.85
- TCBI 47.80
- Support Level
- SWTX $46.21
- TCBI $70.00
- Resistance Level
- SWTX $46.77
- TCBI $73.60
- Average True Range (ATR)
- SWTX 0.15
- TCBI 1.76
- MACD
- SWTX -0.05
- TCBI -0.43
- Stochastic Oscillator
- SWTX 85.71
- TCBI 17.58
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About TCBI Texas Capital Bancshares Inc.
Texas Capital Bancshares Inc is a secured lender, with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. The company's national lines of business provide specialized lending products to businesses throughout the United States. The bank operates in Texas' main metropolitan areas, like Austin, Dallas, Fort Worth, Houston, and San Antonio.